Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.

Isolation and Characterization of Neutralizing Monoclonal Antibodies from a Large Panel of Murine Antibodies against RBD of the SARS-CoV-2 Spike Protein.

Publication date: Jan 05, 2024

The COVID-19 pandemic, once a global crisis, is now largely under control, a testament to the extraordinary global efforts involving vaccination and public health measures. However, the relentless evolution of SARS-CoV-2, leading to the emergence of new variants, continues to underscore the importance of remaining vigilant and adaptable. Monoclonal antibodies (mAbs) have stood out as a powerful and immediate therapeutic response to COVID-19. Despite the success of mAbs, the evolution of SARS-CoV-2 continues to pose challenges and the available antibodies are no longer effective. New variants require the ongoing development of effective antibodies. In the present study, we describe the generation and characterization of neutralizing mAbs against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein by combining plasmid DNA and recombinant protein vaccination. By integrating genetic immunization for rapid antibody production and the potent immune stimulation enabled by protein vaccination, we produced a rich pool of antibodies, each with unique binding and neutralizing specificities, tested with the ELISA, BLI and FACS assays and the pseudovirus assay, respectively. Here, we present a panel of mAbs effective against the SARS-CoV-2 variants up to Omicron BA. 1 and BA. 5, with the flexibility to target emerging variants. This approach ensures the preparedness principle is in place to address SARS-CoV-2 actual and future infections.

Open Access PDF

Concepts Keywords
Covid betacoronaviruses
Isolation mAb panel
Pool neutralizing antibodies
Rich pancoronavirus
Vaccines pandemic preparedness


Type Source Name
disease MESH COVID-19 pandemic
disease VO vaccination
drug DRUGBANK Spinosad
disease VO effective
disease VO immunization
disease IDO assay
disease MESH infections
drug DRUGBANK Coenzyme M
disease VO USA
disease MESH Tumor
disease VO organization
disease VO vaccine
drug DRUGBANK Trestolone
disease MESH infectious diseases
disease MESH viral infections
drug DRUGBANK Palivizumab
disease VO Respiratory syncytial virus
disease MESH emergency
disease VO immunized
disease VO dose
disease IDO blood
disease VO effectiveness
disease VO gene
disease VO efficient
disease VO Viruses
drug DRUGBANK Icodextrin
drug DRUGBANK Angiotensin II
disease IDO production
drug DRUGBANK Tromethamine
drug DRUGBANK Phosphate ion
drug DRUGBANK Imidazole
drug DRUGBANK Sodium lauryl sulfate
disease VO protocol
disease IDO process
drug DRUGBANK L-Glutamine
drug DRUGBANK Streptomycin
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Dimethyl sulfoxide
disease VO volume
disease VO injection
drug DRUGBANK Ethanesulfonic Acid
drug DRUGBANK Sodium acetate
drug DRUGBANK Ethanolamine
drug DRUGBANK Edetic Acid
disease MESH dissociation
disease VO time
drug DRUGBANK Calcium Phosphate
drug DRUGBANK Etodolac
drug DRUGBANK Amino acids
disease IDO infection
disease IDO replication
disease VO Glycoprotein
disease VO efficiency
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Aspartame
disease VO titer
disease VO antibody titer
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Ademetionine
disease IDO algorithm
disease IDO site
drug DRUGBANK L-Aspartic Acid
disease VO intraperitoneal vaccination
disease VO population
disease IDO pathogen
disease MESH Ebola Virus Infection
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Middle East Respiratory Syndrome
disease MESH Respiratory Infections
disease MESH Etiology
disease MESH Critically Ill
disease IDO virulence
disease IDO host
disease MESH Influenza
drug DRUGBANK Guanosine

Original Article

(Visited 1 times, 1 visits today)